Trial Profile
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Acronyms ACE-WM-001
- Sponsors Acerta Pharma
- 09 Jun 2022 According to an AstraZeneca media release, data from this trial will be presented at the European Hematology Association (EHA) Annual Meeting, 2022.
- 02 Dec 2021 Planned End Date changed from 1 Aug 2021 to 31 Dec 2026.
- 21 Jun 2020 Results (N=1040) of pooled analysis from nine clinical studies: ACE-CL-007, ACE-CL-309, ACE-CL-001, 15-H-0016, ACE-LY-002, ACE-LY-003, ACE-LY-004, ACE-MY-001, ACE-WM-001 assessing safety profile of acalabrutinib monotherapy in multiple B-cell malignancies presented at the 25th Congress of the European Haematology Association